Q4 2025 Amneal Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Amneal Pharmaceuticals Inc (AMRX) reported an 8% revenue growth, a 10% increase in adjusted EBITDA, and a 43% rise in adjusted EPS for 2025.
- The company achieved significant portfolio expansion with approvals and launches in complex generics and injectables, which are expected to drive multiyear value.
- Amneal Pharmaceuticals Inc (AMRX) is building a strong position in the biosimilars market, with six biosimilars expected in the US market by 2027.
- The Specialty segment showed strong performance, with CREXONT achieving a 3% market share and expected peak US sales of $300 million to $500 million.
- The company successfully reduced net leverage to 3.5 times and extended debt maturities to 2032, substantially reducing interest costs.
- The Affordable Medicines segment was essentially flat in Q4 2025, reflecting the timing of key products and new launches.
- The Specialty segment is expected to be flat in 2026 due to expected generic erosion of RYTARY, despite the growth of CREXONT.
- Health Care segment revenues are expected to decline in 2026 due to a pivot away from low-margin distribution business and increased competition for generic Entresto.
- The company faces challenges in the supply chain for Iohexol, which may impact the ramp-up of this product.
- Amneal Pharmaceuticals Inc (AMRX) anticipates a temporary pause in growth for the Specialty segment in 2026 before resuming its growth trajectory in 2027.
Good morning, and welcome to the Amneal Pharmaceuticals fourth quarter and full year 2025 earnings call. I'll now hand the call over to Amneal's Head of Investor Relations, Tony Dimeo. Go ahead, please, sir.
Good morning, and thank you for joining the Amneal Pharmaceuticals fourth quarter 2025 earnings call. Today, we issued a press release reporting Q4 results. The earnings press release and presentation are available at amneal.com.
Certain statements made on this call regarding matters that are not historical facts, including, but not limited to, management's outlook or predictions are forward-looking statements that are based solely on information that is now available to us. Please see the section entitled cautionary statements on forward-looking statements for factors that may impact future performance.
We also discuss non-GAAP measures. Information and use of these measures and the reconciliations to GAAP are in the earnings release and presentation.
On the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
